In the first study, plasma samples from 61 patients were tested for Ex19del and L858R by both Sel-Cap and conventional NGS (T790M was not tested because these patients’ PNAclamp tumor biopsies did not include T790M); in the second study, plasma samples from all 185 patients were genotyped for Ex19del, L858R, and T790M by Sel-Cap, and in the third study, plasma samples were collected from 21 patients after they had developed resistance to first-line EGFR-TKIs and genotyped using both Sel-Cap and the NGS cancer panel. Here, EGFR is linked to neoplasm.